BEDMINSTER, NJ-Archimedes Pharma, an international specialty pharmaceutical company, has leased 14,000 square feet at One Crossroads Dr. here. The long-term commitment marks the company’s foray into the US and follows an extensive site search in New Jersey and Pennsylvania; a BEIP grant from the New Jersey Economic Development Authority was the material factor in Archimedes Pharma’s ultimate selection of the Garden State for its new office.
Cushman & Wakefield’s Ron Ganter, Tom Giannone and Chris Kinum--all members of the firm’s Global Life Science Practice group based in East Rutherford, NJ--represented Archimedes Pharma in the transaction. Cushman & Wakefield’s Bill Brown and Josh Cohen, based in Morristown, NJ, served as representatives for property owner Spear Street Capital.
“After an aggressive, six-month search for the right location, Archimedes Pharma found its US home at One Crossroads,” Ganter says, adding that this class A property is situated within New Jersey’s pharmaceutical life science corridor.
The NJ EDA awarded Archimedes a Business Employment Incentive Program grant for its commitment to add up to 75 new jobs in Bedminster. “We were able to work efficiently to secure the incentives, which ultimately enticed our client to choose New Jersey,” Ganter tells GlobeSt.com.
The Cushman & Wakefield team worked closely with Archimedes Pharma’s Jeff Buchalter, president and CEO, and Steve Kanovsky, in-house general counsel, during the assignment.
Want to continue reading?
Become a Free ALM Digital Reader.
Once you are an ALM Digital Member, you’ll receive:
- Breaking commercial real estate news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical coverage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
*May exclude premium content© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
